



NHAM 2021 VIRTUAL PROGRAMME

Day 1, Friday (3rd September 2021)

Time	Hall 1	Hall 2
0800 – 0900	<p>EP Kick-start: Too fast and a tad bit furious</p> <p>Panelists: Nor Halwani HABIZAL Hartini MOHD YUSOF Kantha Rao NARASAMULOO QUEK Chu Zen</p> <p>Case presenters: Sathvinder Singh GIAN SINGH KWAN Yew Fung</p>	<p><u>Free paper abstract presentation 1.0</u> <i>6 abstracts (10 minutes each)</i></p> <p>Moderators: Mansor YAHYA Wan Yus Haniff WAN ISA</p> <p><u>0800-0810</u> FP 1.1 Preliminary Study on Multi-class Heart Disease Detection Model of Echocardiogram Using Deep Learning Khairul Shafiq IBRAHIM</p> <p><u>0810-0820</u> FP 1.2 Validation of an Online STEMI Calculator: A Pilot Project Khairul Shafiq IBRAHIM</p>



0820-0830

FP 1.3

Myocardial Infarction in Young versus Older Adults: A comparison of Risk Factors, Hospital Outcome and Angiographic Characteristic of Acute ST Elevation Myocardial Infarction (STEMI)

[Firdaus MAT LAWI](#)

0830-0840

FP 1.4

A multi-disciplinary approach on treatment adherence and blood pressure control in patients with uncontrolled hypertension

[Shirin Hui TAN](#)

0840-0850

FP 1.5

Direct Acting Oral Anticoagulants in the Treatment of Left Ventricular Thrombus

[Ahmad Bakhtiar MD RADZI](#)

0850-0900

FP 1.6

Review of Killip Classification of STEMI in Non-Cardiac Centre

[Alex KOH Zhi Yang](#)



Time	Hall 1
0900 – 1030	Opening ceremony Moderator: Nik Halmey NIK ZAINAL ABIDIN / Akmal Hakim ARSHAD
0900 – 0910	Welcome speech Wan Azman WAN AHMAD / CHONG Jen Lim
0910 – 0930	Nik Zainal Memorial Lecture The memorable journey of clinical practice guidelines development in Malaysia Jeyamalar RAJADURAI
0930 – 0950	ACC Plenary Lecture Cardiac Care in Women: Emerging Risk Factors Dipti ITCHHAPORIA <i>President of American College of Cardiology</i>
0950 – 1010	ESC Plenary Lecture What Cardiac CT Taught Us About Prevention Stephan ACHENBACH <i>President of European Society of Cardiology</i>
1010 – 1030	FNHAM Virtual Convocation Video presentation by NHAM



Time	Hall 1	Hall 2
1030 – 1145	<p><u>Symposium 1</u> NSTE-ACS</p> <p>Chairpersons: Aizai Azan ABDUL RAHIM Omar ISMAIL</p>	<p><u>Symposium 2</u> Valvular heart disease – you don't want to miss this echocardiogram image loaded session!</p> <p>Chairpersons: OTEH Maskon Muhamad Ali SHEIKH ABDUL KADER</p>
1030 – 1050	<p>1. Managing NSTE – ACS in clinical practice: insights from the latest Malaysian CPG Jeyamalar RAJADURAI</p>	<p>1. Severe asymptomatic valvular heart disease: guidelines and perspective Mohd Rahal YUSOFF</p>
1050 – 1110	<p>2. Paradigm shift in NSTE – ACS treatment strategy – recent developments with OAPs Rosli MOHD ALI</p>	<p>2. Rheumatic heart disease in Malaysia: A forgotten entity? LIEW Hong Bang</p>
1110 – 1130	<p>3. Normal or non-obstructive CAD with elevated troponins on presentation – Should I be bothered? Asri Ranga ABDULLAH RAMAIAH</p>	<p>3. Infective endocarditis: current approach Hafisyatul Aiza ZAINAL ABIDIN</p>
1130 – 1145	Q & A	Q & A
1145 – 1245	<p><u>Sponsored symposium 1 - Novartis</u> HF across the spectrum of ejection fraction – What is it all about?</p> <p>Chairperson: CHEE Kok Han</p>	<p><u>Free paper abstract presentation 2.0</u> <i>6 abstracts (10 minutes each)</i></p> <p>Moderators: Ahmad Fazli ABDUL AZIZ</p>



1145 – 1150

Opening remarks

[CHEE Kok Han](#)

1150 – 1205

Latest HF guidelines and consensus in 2021

[Roy S GARDNER – Scotland](#)

1205 – 1220

Breaking the vicious cycle of readmission in HF

[Michele SENNI – Italy](#)

1220 – 1235

LVEF: Is it still meaningful in HF?

[Akshay S DESAI – USA](#)

1235 – 1245

Panel discussion

[All panellist](#)

[Mohd Firdaus HADI](#)

1145 – 1155

FP 2.1

Performance and 12-month Outcomes of a Wire-free Fractional Flow Reserve System for assessment of coronary artery disease – first experience in South-East Asia

[Chandan Deepak BHAVNANI](#)

1155-1205

FP 2.2

Transfer of Patients to Spoke Hospital after Primary PCI. A Novel Strategy to Optimize Cardiology Care in Busy Cardiac Centre.

[Julian TEY Hock Chuan](#)

1205-1215

FP 2.3

Intravascular Ultrasound (IVUS) Guidance Improves Clinical Outcome for Patients Who Underwent Implantation of Drug-Eluting Stents (DES) in Unprotected Left Main Coronary Artery (ULMCA) Compared with Angiography Guidance Alone

[QUAH Wy Jin](#)

1215-1225

FP 2.4

Single Centre Registry: Acute Outcomes of Coronary Orbital Atherectomy in Calcified Coronary Arteries

[Mahes Arvin PREMANANTH](#)



		<p><u>1225-1235</u> FP 2.5 3 - year Percutaneous Coronary Intervention (PCI) Procedures and Outcomes in a Dedicated Cardiovascular Centre Thavin Kumar MATHANA SUNDRAM</p> <p><u>1235-1245</u> FP 2.6 Clinical Presentation, Treatment and 2-Year Prognosis of Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA): A Single Centre Study in Malaysia Ramachandran SATHAPPAN</p>
<p>1245 – 1400</p> <p>1245 – 1305</p> <p>1305 – 1325</p>	<p><u>Symposium 3</u> STEMI</p> <p>Chairpersons: Kamaraj SELVARAJ Kumara Gurupparan GANESAN</p> <p>1. ECG in STEMI: Let's go back to basics Abdul Raqib ABDUL GHANI</p> <p>2. Pharmaco-invasive treatment in STEMI: Case based Ramesh Singh VERIAH</p>	<p><u>Heart Failure Research Award</u> <i>Supported by an unrestricted educational grant by Servier</i></p> <p>Chairperson: Muhammad Dzafir ISMAIL</p> <p>Judges:</p> <ol style="list-style-type: none"> Sofian JOHAR ONG Hean Yee Sree Raman KUNJAPPAN David CHEW Soon Ping



<p>1325 – 1345</p> <p>1345 – 1400</p>	<p>3. STEMI complications: recognition and management Al Fazir OMAR</p> <p>Q & A</p>	<p>5. Hamat Hamdi CHE HASSAN</p> <p><u>1245 – 1300</u> HFRA 1: Clinical Outcomes and Predictors of Improved Left Ventricular Ejection Fraction in Heart Failure with Reduced Ejection Fraction due to Non-Ischemic Cardiomyopathy LING Hwei Sung</p> <p><u>1300 – 1315</u> HFRA 2: Clinical Characteristics of Patients with Hereditary Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Sarawak CHEN Lean Seng</p> <p><u>1315 – 1330</u> HFRA 3: Diagnostics at Admission across EF Subgroup - Data from the Malaysian Heart Failure (MYHF) Registry Alexander LOCH</p> <p><u>1330 – 1345</u> HFRA 4: Demographic characteristics differences across EF subgroups in the Malaysian heart failure (MyHF) registry Hafisyatul Aiza ZAINAL ABIDIN</p>
<p>1400 – 1415</p>	<p>COVID-19: What every doctor should know? 'Let's hear directly from the expert' <i>Overview of COVID-19 management</i></p> <p>Moderators: Wan Yus Haniff WAN ISA Ahmad Fazli ABDUL AZIZ</p>	<p><u>1345 – 1400</u> HFRA 5: Hospitalization Outcomes at Discharge for HF Patients Stratified by EF Subgroups of National Malaysia Heart Failure (MyHF) Registry Abdul Muizz ABD MALEK</p>



	<p>Panelist: Sazali BASRI</p>	<p><u>1400 – 1415</u> HFRA 6: Real world clinical outcomes of angiotensin receptor-neprilysin inhibitor (ARNI) in patients with heart failure with reduced ejection fraction: A Malaysian experience Azmee MOHD GHAZI</p>
1415 – 1530	<p><u>Symposium 4</u> Atrial fibrillation 1.0</p> <p>Chairpersons: Kantha Rao NARASAMULOO Mohd Shawal Faizal MOHAMAD</p>	<p><u>Symposium 5</u> Women's heart</p> <p>Chairpersons: Effarezan ABDUL RAHMAN Nor Ashikin MD SARI</p>
1415 – 1435	<p>1. Anti-coagulation for NVAf patients with high bleeding risk Gary LEE Chin Keong</p>	<p>1. Estrogen and the heart – Risks, benefits and side-effects Emily TAN Lay Koon</p>
1435 – 1455	<p>2. Anti-coagulation in patients with renal impairment: Finding the right balance CHEE Kok Han</p>	<p>2. Cardiovascular investigative tools – which one has women at heart ONG Mei Lin</p>
1455 – 1515	<p>3. A new decade for patients with AF: protect the irreplaceable Imran ZAINAL ABIDIN</p>	<p>3. Women and CAD in Malaysia – do they really have better survival? LEE Chuey Yan</p>
1515 – 1530	<p>Q & A</p>	<p>Q & A</p>



Time	Hall 1	Hall 2
1530 – 1645	<p><u>Symposium 6</u> Diabetes mellitus 1.0</p> <p>Chairpersons: TIANG Soon Wee Anwar Irawan RUHANI</p>	<p><u>Symposium 7</u> Advanced anti-lipids therapy</p> <p>Chairpersons: LEE Zhen-Vin Rizmy NAJME KHIR</p>
1530 – 1550	<p>1. SU in ASCVD T2D: Zero or Hero? Alexander TAN</p>	<p>1. Protect from the Start: Lipids, atherosclerosis and CV outcomes Gary LEE Chin Keong</p>
1550 – 1610	<p>2. GLP-1 RA and renal protection CHOW Yok Wai</p>	<p>2. Managing patients with dyslipidemia – role of PCSK9 inhibitors in optimizing patient care Rohit KHURANA – Singapore</p>
1610 – 1630	<p>3. Managing diabetes – Looking through a cardiologist lens Azhari ROSMAN</p>	<p>3. Beginning of A New Era of Low LDL-C with new frontiers on the horizon Kausik RAY – United Kingdom</p>
1630 – 1645	<p>Q & A</p>	<p>Q & A</p>
1645 – 1745	<p><u>Sponsored symposium 2 - Menarini</u> 'Optimizing patient outcomes in clinical practice'</p> <p>Chairperson: NG Wai Kiat</p>	<p><u>Sponsored symposium 3 - Novo Nordisk</u> SUSTAIN-ing control in diabetes management: What matters!</p> <p>Chairperson: Azmee MOHD GHAZI</p>



	<p><u>1645 – 1650</u> Opening remarks NG Wai Kiat</p> <p><u>1650 – 1715</u> RCT and RWE in patients with NVAF: What do we know so far for edoxaban? CHIANG Chern-En – <i>Taiwan</i></p> <p><u>1715 – 1735</u> Heart rate lowering and hypertension outcome: What's new from the BENEFIT study? David QUEK Kwang Leng</p> <p><u>1735 – 1745</u> Panel discussion All panellist</p>	<p><u>1645 – 1650</u> Opening remarks Azme MOHD GHAZI</p> <p><u>1650 – 1700</u> CAPTURE-ing the killer in T2D: CV disease Azme MOHD GHAZI</p> <p><u>1700 – 1725</u> Sustaining control in diabetes management Michael NAUCK – <i>Germany</i></p> <p><u>1725 – 1740</u> Bench to bedside: case study presentation and panel discussion All panellist</p> <p><u>1740 – 1745</u> Closing remarks Azme MOHD GHAZI</p>
<p>1745 – 1845</p>	<p><u>Free paper abstract presentation 3.0</u> 6 abstracts (10 minutes each)</p> <p>Moderators: CHOR Chee Ken FOO Yoke Loong</p>	<p><u>Free paper abstract presentation 4.0</u> 6 abstracts (10 minutes each)</p> <p>Moderators: Sazli Shahan KASIM Asri SAID</p>



1745-1755

FP 3.1

Malaysian Heart Failure (MYHF) Registry Substantiates High Burden of Comorbidities Across the Continuum of Ejection Fraction in Malaysian HF Patients

[Adelyn Nisha NERIN HENRY](#)

1755-1805

FP 3.2

Echocardiographic Findings and Risk Factors in Young Adults with Heart Failure

[Naim ABDUL MALEK](#)

1805-1815

FP 3.3

Demographic and characteristic of patients admitted with heart failure: Interim analysis of Malaysia Heart Failure (MYHF) Registry

[Wan Azman WAN AHMAD](#)

1815-1825

FP 3.4

Heart Failure Frequent Flyer Programme Htar: A Life-Saver?

[Nur Asyikin MOHD YUNUS](#)

1825-1835

FP 3.5

1745-1755

FP 4.1

Haemodynamic Analysis on the Performance of Transcatheter Heart Valve

[NG Fei Chong](#)

1755-1805

FP 4.2

Comparative Study of Mechanical and Transcatheter Heart Valves for Aortic Valve Replacement

[NG Fei Chong](#)

1805-1815

FP 4.3

Efferocytosis of Oxidized Low-Density Lipoprotein Generated Apoptotic Bodies by Primary M1 and M2 Macrophages Isolated from Non-obstructive and Obstructive Coronary Artery Disease Patients

[Fatin Najiah MOHD IDRUS](#)

1815-1825

FP 4.4

Cost-Effectiveness Analysis of Apixaban for the Treatment of Atrial Fibrillation from a Public Payer's Perspective in Malaysia

[Kenneth LEE](#)

1825-1835

FP 4.5



Hematocrit Change as A Predictor of Readmission for
Decompensated Heart Failure: A Retrospective Single Centre Study

[Mohd Aizuddin MOHD ZULASTRI](#)

1835-1845

FP 3.6

Treatment pattern amongst hospitalized HF patients stratified by EF
subgroups: Interim review of National Malaysian Heart Failure
(MYHF) Registry

[Azmee MOHD GHAZI](#)

Effectiveness of an Intervention to Improve Knowledge of
Streptokinase and Streptokinase Card among Post-STEMI Patients in
a Malaysian Tertiary Hospital: A Randomised Controlled Trial

[ANG Wei Chern](#)



Day 2, Saturday (4th September 2021)

Time	Hall 1	Time	Hall 2
0800 – 0900	<p><u>Interactive cardiac imaging case session</u> Valvular heart disease case review</p> <p>Chairperson: Mohd Rahal YUSOFF</p> <p>1. 'Strangers in the night' Mohd Shawal Faizal MOHAMAD</p> <p>2. 'Now you see me' Gurudevan MAHADEVAN</p> <p>Panellist: Shahrul Amry HASHIM Barakath Badusha ABDUL KAREEM KAM Jiyen</p>	0800 – 0840	<p>Conversations: Covid-19 and the heart 'What should a cardiologist know about Covid-19?' <i>Issues related to cardiac manifestation and vaccination</i></p> <p>Moderators: Alan FONG Yean Yip Nik Halmey NIK ZAINAL ABIDIN</p> <p>Panellist: Yasmin MOHAMED GANI LIEW Houg Bang</p>
0900 – 1015	<p><u>Symposium 8</u> Heart failure 1.0</p> <p>Chairpersons: Wan Azman WAN AHMAD</p>	0840 – 1015	<p><u>Symposium 9</u> Atrial fibrillation 2.0</p> <p>Chairpersons: MA Soot Keng Ahmad Nizar JAMALUDDIN</p>



0900 – 0920	TEOH Chee Kiang 1. Back to the basics: How heart rate remains a key factor in deciding heart failure outcomes CHOO Gim Hooi	0840 – 0900	1. Anti-coagulation care in AF: Safety in focus? Gary LEE Chin Keong
0920 – 0940	2. In-hospital initiation of ARNi: A new Paradigm Shift for acute decompensated heart failure? Azhari ROSMAN	0900 – 0940	2. Managing bleeding risk with anti-coagulation therapy Christopher GRANGER – USA
0940 – 1000	3. How should I work up my patient who have just recovered from acute heart failure? CHAM Yee Ling	0940 – 1000	3. When it is raining blood, an umbrella certainly comes in handy – experience with Watchman’s device Imran ZAINAL ABIDIN
1000 – 1015	Q & A	1000 – 1015	Q & A
Time	Hall 1	Hall 2	
1015 – 1130	<u>Symposium 10</u> Cardiac arrhythmia Chairpersons: Zulkeflee MUHAMMAD KOH Kok Wei	<u>Symposium 11</u> Peripheral arterial disease Chairpersons: CHOONG Choon Hooi Abdul Wahab UNDOK	
1015 – 1035	1. Supraventricular tachycardia: things not to be missed (investigation and management) Ahmad Fazli ABDUL AZIZ	1. How to perform screening for PAD in clinical practice? Jayakhanthan KOLANTHAIVELU	



1035 – 1055	2. Post resus VF with normal coronaries Saravanan KRISHINAN	2. Endovascular interventions for PAD – current state of the art Ahmad Rafizi Hariz RAMLI
1055 – 1115	3. PVCs in normal heart – tips from the expert Nor Halwani HABIZAL	3. Improving MACE and MALE in patients with chronic coronary syndrome (CCS) and peripheral artery disease (PAD) Shaiful Azmi YAHAYA
1115 – 1130	Q & A	Q & A

Time	Hall 1	Time	Hall 2
1130 – 1300	<p>'Young Investigator Award'</p> <p>Chairpersons: CHONG Jen Lim Muhammad Dzafir ISMAIL</p> <p>Judges:</p> <ol style="list-style-type: none"> Wan Azman WAN AHMAD – Malaysia Sofian JOHAR – Brunei Isman FIRDAUS – Indonesia ONG Hean Yee – Singapore KYAW Soe Win – Myanmar Gilbert C VILELA – Philippines Rungroj KRITTAYAPHONG – Thailand 	1130 – 1245	<p><u>Symposium 12</u> Anti-platelets</p> <p>Chairpersons: Zulhilmi YAAKOB Dharmaraj KARTHIKESAN</p>
		1130 – 1150	1. Role of anti-platelets in primary prevention of future cardiovascular events Benjamin LEO Cheang Leng
		1150 – 1210	2. Mitigating the bleeding risk along the ACS patient journey: from initiation to maintenance Jeyamalar RAJADURAI



1130 – 1145	<p><u>YIA 1</u> Genomic Risk Score Associated with Young Myocardial Infarction at UITM Medical Centre Huzairi Bin SANI</p>	1210 – 1230	3. Anti-platelets and anti-coagulations – buddies best kept separated? LIM Chiao Wen
1145 – 1200	<p><u>YIA 2</u> Evaluation of Relationship Between Left Ventricular Outflow Tract Diameter and Body Size in a Multi-ethnic Southeast Asian Population and The Accuracy of Size-Adjusted Left Ventricular Outflow Tract Diameter Reference Values in Patients with Severe Aortic Stenosis THIEN Lee Karl</p>	1230 – 1245	Q & A
1200 – 1215	<p><u>YIA 3</u> Preliminary Results of 24-Hour Holter and 7-Day Single-Use, Water-Resistant, Wireless, Cardiac Patch Electrocardiogram Monitoring for Detecting Atrial Fibrillation After An Acute Cerebral Ischemic Event: A Comparative Analysis Diana FOO Hui Ping</p>	1245 – 1300	<p>‘Insights on vaccine-induced thrombotic thrombocytopenia’</p> <p>Moderators: Effarezan ABDUL RAHMAN Akmal Hakim ARSHAD</p> <p>Panellist: Veena SELVARATNAM</p>
1215 – 1230	<p><u>YIA 4</u> Three-year Clinical Outcome of Fractional Flow Reserve Guided Coronary Revascularization with Monorail Pressure Microcatheter Chandan Deepak BHAVNANI</p>		



1230 – 1245	<p><u>YIA 5</u> Preoperative Coronary Angiography in Non-Coronary Cardiac Surgery: Is There Any Role in Asymptomatic Patients? HO Yan Le</p>		
1245 – 1300	<p><u>YIA 6</u> Intermediate-Term Safety and Performance of Conduction System Pacing: Single Centre Experience THIEN Lee Karl</p>		
Time Hall 1		Hall 2	
1300 – 1400	<p><u>Sponsored symposium 4 - Boehringer Ingelheim</u> What's on the horizon for HF management?</p> <p>Chairperson: Jeyamalar RAJADURAI</p> <p><u>1300 – 1305</u> Welcome and introduction Jeyamalar RAJADURAI</p> <p><u>1305 – 1315</u> The link between T2D, CKD and HF David CHEW Soon Ping</p>		<p><u>Sponsored symposium 5 - Servier</u> Classical vs contemporary anti-anginal agents: A quality choice or a quantity choice?</p> <p>Chairperson: LAM Kai Huat</p> <p>Practical cases: Personalizing treatment approach in the management of CCS Luis Henrique W GOWDAK – Brazil</p>



	<p><u>1315 – 1340</u> Clinical value of SGLT2i in the heart failure spectrum: An update from EMPEROR program <i>Michael BOEHM – Germany</i></p> <p><u>1340 – 1355</u> Panel discussion <i>All panellist</i></p> <p><u>1355 – 1400</u> Closing remarks <i>Jeyamalar RAJADURAI</i></p>	
<p>1400 – 1515</p> <p>1400 – 1420</p> <p>1420 – 1440</p>	<p><u>Symposium 13</u> Hypertension 1.0</p> <p>Chairperson: <i>NG Wai Kiat</i> <i>Effarezan ABDUL RAHMAN</i></p> <p>1. Treating hypertension with the end in mind – an evidence-based approach <i>Abdul Rashid ABDUL RAHMAN</i></p> <p>2. Clinical significance of albuminuria in hypertension management – a nephrologist’s perspective <i>Akira WU Yik-Tian – Singapore</i></p>	<p><u>Symposium 14</u> Atherosclerotic Cardiovascular Disease (ASCVD)</p> <p>Chairpersons: <i>Ahmad Syadi MAHMOOD ZUHDI</i> <i>Mohd Kamal MOHD ARSHAD</i></p> <p>1. Atherosclerosis – a complex process beyond atherogenesis <i>Sazzli Shahlan KASIM</i></p> <p>2. Improving CV risk management in patients with obesity <i>Azhari ROSMAN</i></p>



1440 – 1500	3. Sympathetic overdrive in the management of hypertension LIM Bee Chian	3. Statin in the prevention of ASCVD in post-stroke Pierre AMARENCO – France
1500 – 1515	Q & A	Q & A
1515 – 1630	<u>Symposium 15</u> Diabetes mellitus 2.0 Chairpersons: LAM Kai Huat Balachandran KANDASAMY	<u>Symposium 16</u> Beyond ACS Chairpersons: Zubin Othman IBRAHIM Mohamad Nazrulhisham MAD NASER
1515 – 1535	1. CV outcomes with GLP-1RAs: Interpretations and Insights CHEE Kok Han	1. Optimizing Antiplatelet Therapy in CAD Patients Aslannif ROSLAN
1535 – 1555	2. GLP-1 RA and stroke prevention CHAN Siew Pheng	2. Early LDL-C intervention post ACS for long-term outcomes Azhari ROSMAN
1555 – 1615	3. Emerging evidence on management of CAD in patients with T2DM John CAMM – United Kingdom	3. Improving treatment effectiveness & efficiencies in stable coronary artery disease Johan Rizwal ISMAIL
1615 – 1630	Q & A	Q & A



Time	Hall 1	Hall 2
1630 – 1730	<p><u>Sponsored symposium 6 - Astra Zeneca</u> Defining the strategy, delivering the life-saving efficacy</p> <p>Chairperson: CHEE Kok Han</p> <p><u>1630 – 1635</u> Introduction CHEE Kok Han</p> <p><u>1635 – 1650</u> From at risk to high-risk HF, optimizing dapagliflozin for clinical benefit Norlela SUKOR</p> <p><u>1650 – 1705</u> Sustained and early efficacy of dapagliflozin, improving quality of life in heart failure patient CHEE Kok Han</p> <p><u>1705 – 1720</u> Precious pair, what an ounce of prevention is worth LIM Soo Kun</p> <p><u>1720 – 1730</u> Panel discussion and closing All panellist</p>	<p><u>Sponsored symposium 7 - Bayer</u> 'Rivaroxaban: Beyond anti-coagulation'</p> <p>Chairperson: TIANG Soon Wee</p> <p><u>1630 – 1730</u> Agenda:</p> <ol style="list-style-type: none"> 1. Debunking the myth in AF 2. Protection for AF beyond anti-coagulation 3. Mitigating cardiovascular and mortality outcomes in CCS patients <p>Panellist: Robert WELSH – Canada Wan Azman WAN AHMAD Muhammad Dzafir ISMAIL</p>



Time	Hall 1	Hall 2
1730 – 1830	<p><u>Sponsored symposium 8 - Menarini</u> 'Expanding our knowledge of NOACs in AF'</p> <p>Chairperson: CHOO Gim Hooi</p> <p><u>1730 – 1735</u> Opening remarks CHOO Gim Hooi</p> <p><u>1735 – 1755</u> AF in Asian context – Applying results from ENGAGE AF-TIMI 48 Robert GIUGLIANO – USA</p> <p><u>1755 – 1820</u> Anti-thrombotic therapy in AF patients undergoing PCI – Where do we stand? Andreas GOETTE – Germany</p> <p><u>1820 – 1830</u> Panel discussion All panellist</p>	<p><u>Sponsored symposium 9 - Zuellig-Pharma</u> SGLT2i & GLP-1 RA – Are they the same?</p> <p>Chairperson: Azhari ROSMAN</p> <p><u>1730 – 1735</u> Welcome remarks by chairperson Azhari ROSMAN</p> <p><u>1735 – 1800</u> The perspectives in primary and secondary CV risk reduction in T2DM patients Santiago Tofe POVEDANO – Spain</p> <p><u>1800 – 1820</u> Patient case sharing CHEE Kok Han</p> <p><u>1820 – 1830</u> Panel discussions and summary All faculty</p>



Day 3, Sunday (5th September 2021)

Time	Hall 1	Hall 2
0800 – 0900	<p>EP rise and show: OMG, my heart rate is too slow</p> <p>Panellists: Ahmad Suhaimi MUSTAFA Hazleena MOHAMED HASNAN TAN Nee Hooi</p> <p>Case presenters: FOO Jhi Hui Kurnia Prima Sawai SUARDI</p>	<p><u>Free paper abstract presentation 5.0</u> <i>6 abstracts (10 minutes each)</i></p> <p>Moderators: Norzian ISMAIL Muhammad Imran ABDUL HAFIDZ</p> <p><u>0800-0810</u> FP 5.2 Comparison on Outcomes of Pharmaco-invasive Strategy, Delayed Routine Percutaneous Coronary Intervention (PCI) and Optimal Medical Therapy (OMT) After Successful Thrombolysis in Patients with ST Elevation Myocardial Infarction (STEMI): 1 Year Data from A Single Centre KWAN Yew Fung</p> <p><u>0810-0820</u> FP 5.3 Phone-based General Cardiology Follow-up Clinic in a Tertiary Center during COVID-19 Pandemic: Patient and Clinician Experience. Muhammad Hanis MUHAMAD HAMIDI</p> <p><u>0820-0830</u></p>



		<p>FP 5.4 Anticoagulation Control in Atrial Fibrillation Patients with Chronic Kidney Disease Receiving Warfarin for Stroke Prevention: The West Birmingham AF Project Hanis Hanum ZULKIFLY</p> <p><u>0830-0840</u> FP 5.5 Safety and Outcome of Non-Valvular Atrial Fibrillation Cryoablation; A Single Centre Registry of Northern Malaysia Mohd Ridzuan MOHD SAID</p> <p><u>0840-0850</u> FP 5.6 Utility of Dutch Lipid Clinic Network Score to Estimate Prevalence of Familial Hypercholesterolemia in Patients with ST-Elevation Myocardial Infarction CHOW Han Bing</p>
<p>0900 – 1015</p>	<p><u>Symposium 17</u> Hypertension 2.0</p> <p>Chairpersons: Alan FONG Yean Yip Nik Halmey NIK ZAINAL ABIDIN</p>	<p><u>Symposium 18</u> NHAM-SCMR Joint Symposium <i>Initiative by SCMR Advocacy Committee</i></p> <p>Chairperson: Rafidah ABU BAKAR Nor Hanim MOHD AMIN</p>



0900 – 0920	<p>1. Should I increase the dose or should I not? Dilemma in achieving optimal blood pressure control. <i>Azani MOHAMED DAUD</i></p>	<p>1. SCMR experience in developing CMR service globally, cost-effectiveness of CMR, utilisation of CMR and overcoming the barriers <i>Lilia M SIERRA-GALAN – Mexico</i></p>
0920 – 0940	<p>2. When should I take my pressure pills? Daytime vs nocturnal prescriptions <i>Nik Sherina Haidi HANAFI</i></p>	<p>2. CMR in cardiomyopathies (ischaemic and non-ischaemic) <i>Mona BHATIA – India</i></p>
0940 – 1000	<p>3. Leading with evidence: Latest data on renal denervation <i>ONG Tiong Kiam</i></p>	<p>3. CMR in assessment of cardiac masses <i>Dudley PENNELL – United Kingdom</i></p>
1000 – 1015	Q & A	Q & A
1015 – 1130	<p><u>Symposium 19</u> Heart failure 2.0</p> <p>Chairpersons: <i>Alexander LOCH</i> <i>Abdul Muizz ABD MALEK</i></p>	<p><u>Symposium 20</u> Grown-up with heart diseases</p> <p>Chairpersons: <i>Akmal Hakim ARSHAD</i> <i>CHAM Yee Ling</i></p>
1015 – 1035	<p>1. Drugs optimization in stable heart failure patients – A sneak peek into MyHF registry <i>Azmee MOHD GHAZI</i></p>	<p>1. Kawasaki disease – coronary artery thrombosis <i>HUNG Liang Choo</i></p>
1035 – 1055	<p>2. Device therapies for heart failure – When should you refer? <i>MA Soot Keng</i></p>	<p>2. Unoperated septal defects – how do we monitor and when to intervene? <i>Martin WONG Ngie Liong</i></p>



<p>1055 – 1115</p> <p>1115 – 1130</p>	<p>3. Restore a broken heart: Is it possible? TAN Chiang Soo</p> <p>Q & A</p>	<p>3. Challenges in managing patients during transition phase: paediatrics vs adult cardiology Geetha KANDAVELLO</p> <p>Q & A</p>
<p>1130 – 1230</p>	<p><u>Sponsored symposium 10 - Servier</u> 'When less is more' Single pill combination as hypertension frontliner</p> <p>Chairperson: NG Wai Kiat</p> <p>Speaker: Vijaya Bharath RAMASAMY</p>	<p><u>Free paper abstract presentation 6.0</u> <i>6 abstracts (10 minutes each)</i></p> <p>Moderators: Mohd Sapawi MOHAMED Patrick TIAU Wei Jyung</p> <p><u>1130-1140</u> FP 6.1 Impact of 2016 ASE/EACVI Recommendations on Evaluation of Left Ventricular Diastolic Function and Predicting Cardiovascular Outcomes in Patients with Diabetes and Hypertension Without Prior Adverse Cardiac Events Diana FOO Hui Ping</p> <p><u>1140-1150</u> FP 6.2 Characteristics of Patients with Myocardial Infarction and Their Outcomes: A Rural Primary Healthcare Setting in Lubok Antu District, Sarawak, Malaysia</p>



Caryn LIM Tsujean

1150-1200

FP 6.3

Presence of Ramus Intermedius Increases the Risk of Atherosclerotic Plaque Formation at the Left Main Bifurcation's Region: A Retrospective Study from CT Coronary Angiography in UMMC

Nurul Sazmi ROSANI

1200-1210

FP 6.4

Elevated Highly-Sensitive Troponin T and Pulse Wave Velocity in Mild Chronic Kidney Disease

Ahmad Bakhtiar MD RADZI

1210-1220

FP 6.5

A Review of STEMI Cases In Sarawak General Hospital: A Comparison To National Data

Julian TONG Wei Ee

1220-1230

FP 6.6

Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in Patients with STEMI. A Retrospective Observational Single Centre Analysis

PANG Ing Xiang



Time	Hall 1	Time	Hall 2
1230 – 1345	<p><u>Symposium 21</u> 'Blockbuster updates'</p> <p>Chairpersons: CHONG Jen Lim Muhammad Dzafir ISMAIL</p>	1230 – 1345	<p><u>Symposium 22</u> Expanded Cardiology</p> <p>Chairpersons: TIANG Soon Wee Wan Yus Haniff WAN ISA</p>
1230 – 1300	<p>1. Updates from ACC ACC.21 Highlights Dipti ITCHHAPORIA <i>President of American College of Cardiology</i></p>	1230 – 1250	<p>1. Potentially inappropriate medications in the older person – current guidelines TAN Kit Mun</p>
1300 – 1330	<p>2. Take-aways from ESC Thomas LÜSCHER <i>Secretary/Treasurer of European Society of Cardiology</i></p>	1250 – 1310	<p>2. CAD and CKD – the deadly duo! Maisarah JALALONMUHALI</p>
1330 – 1345	<p>Discussants Wan Azman WAN AHMAD Alan FONG Yean Yip ONG Tiong Kiam LIEW Hong Bang</p>	1310 – 1330	<p>3. Sleep-disordered breathing and cardiovascular disease: two sides of the same coin? Lily Diana ZAINUDIN</p>
		1330 – 1345	Q & A
Time	Hall 1		
1345 – 1400	<p><u>Closing ceremony</u> Closing speech and winner announcement Moderators: Akmal Hakim ARSHAD / Effarezan ABDUL RAHMAN</p>		